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Abstract
A 60-year-old man is presented with progressive involuntary muscle movements
and neuropsychiatric symptoms who developed a variety of additional com-
plaints over 2 years. Brain imaging revealed bilateral basal ganglia calcifications
suggesting primary familial brain calcification. Analysis of the SLC20A2 gene
revealed a missense mutation (c.541C>T, p.(Arg181Trp)), in silico predicted to
be deleterious and not found in available databases. Segregation analysis con-
firmed his asymptomatic father to harbor the same mutation, though on brain
imaging basal ganglia calcifications were found. This report illustrates the
intrafamilial variability of the phenotype and generalized myoclonus as the pre-
senting symptom.
Introduction
Primary familial brain calcification (PFBC, OMIM#213600)
is an autosomal dominant neuropsychiatric disorder with
clinical and molecular heterogeneity. Symptoms include
migraine, mood swings, parkinsonism, cognitive decline
and psychiatric manifestations with a variable age of onset
between 30 and 60 years. Currently, four genes have been
associated with PFBC: SLC20A2 (OMIM*158378),
PDGFRB (OMIM*173410), PDGFB (OMIM*190040), and
XPR1 (OMIM*605237), though no clear genotype–pheno-
type correlation could be established.1 However, SLC20A2
and XPR1 have been linked to phosphate metabolism while
PDGFB and PDGFRB are connected to the blood–brain
barrier integrity and pericyte maintenance.1 These four
genes represent approximately 60% of all familial cases,
with most mutations (40%) found in SLC20A2, encoding
the inorganic phosphate transporter PIT-2.2,3 The diagnosis
of PFBC is established with visualization of bilateral calcifi-
cation of the basal ganglia on neuroimaging; presence of
progressive neurologic dysfunction, in the absence of meta-
bolic, infectious, toxic or traumatic cause. Identification of
a heterozygous pathogenic variant by molecular genetic
testing confirms the clinical diagnosis of PFBC. We report
a family who presented with a variable presentation of
PFBC, including progressive myoclonus, due to a likely
pathogenic variant in the SLC20A2 gene.
Case Presentation
The proband is a 62-year-old man who has been suffering
since 2 years from involuntary muscle movements and
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twitching of the lower limbs, which were initially thought
to be segmental myokymias. Initially, he described these
as brief electric shock sensations in the legs, predomi-
nantly occurring as 3–4 min episodes in the evening or
while falling asleep, keeping him awake. Physical exami-
nation confirmed the muscle undulating twitches and a
discrete positional tremor of the hands. Electromyography
was performed but showed neither myokymic discharges
nor myopathic or neuropathic changes. During the next
months, involuntary movements – mainly muscle fascicu-
lations – also arose in the arms and torso. The patient
complained of neuropathic pain in the upper and lower
limbs with a warm and burning sensation, and associated
with muscle cramps and stiffness. The complaints were
initially episodic and were relieved through exercise.
However, the symptoms continued to worsen progres-
sively over a period of 2 years, particularly in the legs.
There were no seizures or epilepsy.
The medical history of the proband was further
remarkable for a compression fracture of a cervical verte-
bra due to osteoporosis as well as mood swings at age 60
(mainly recurrent depressive moods, potentially as a result
of the occurrence of the involuntary movements) for
which he was treated with carbamazepine.
Brain imaging revealed bilateral basal ganglia calcifica-
tions, lenticulostriatal and in the globus pallidus (Fig. 1A
and B). A small older lacunar infarction was noted in the
pedunculus cerebri of the mesencephalon. Comprehensive
neurological (electromyography, electroencephalogram),
metabolic (serum electrolytes, thyroid and parathyroid
hormones, calcitonin, albumin, billirubin, transaminases,
gamma GT, cholesterol, triglyceride, vitamin B12, vitamin
D, folate, urea, and creatinine; urine elektrolytes, urea
and creatinine) and infectious (toxoplasmosis, cytomega-
lovirus virus) examinations were all normal. Family his-
tory was unremarkable for neurological problems, apart
from unspecified psychiatric problems in his sister.
Within 2 years after the diagnosis, the patient showed
a general worsening of the phenotype. The involuntary
movements became generalized, occurring throughout the
day but most severe in the evening. They could be
provoked by yawning. Novel symptoms, which occurred
during this period, included dizziness, ocular pain, head-
aches associated with photophonofobia and rustling
sounds. The latter improved using a combined tricyclic
anti-depressive and anti-psychotic drug (melitracen and
flupentixol). Cognition remained normal at all times. Fur-
thermore, the proband developed complaints of tinnitus
as well as bilateral hearing loss for which hearing aids
were necessary. Audiometry confirmed bilateral symmetri-
cal neurosensorial hearing loss in the high tones (right:
45 dB at 8000 Hz; left 65 dB at 4000 Hz). Ophthalmolog-
ical evaluation revealed mild cataract. The family history
of the proband remained unchanged. At age 65, begin-
ning of nuclear cataract was noted.
Molecular Analysis
Because of the brain imaging findings, PFBC was sus-
pected and molecular analysis of the four known PFBC
genes was performed. PCR amplification and subsequent
Sanger sequencing of all protein-coding exons and exon–
A B C
Figure 1. Brain imaging of the proband and his father. In the proband, T2* shows multiple hypointense lesions in the globus pallidus (A, B).
There is no surrounding edema and no signs of leukoencefalopathy can be noted. In the proband’s father, bilateral hyperintense calcifications in
the basal ganglia were noted, without white matter involvement (C).
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intron boundaries of SLC20A2, PDGFB, PDGFRB, and
XPR1 genes were performed. Novelty of the variants was
investigated using the online databases: dbSNP142 (http://
www.ncbi.nlm.nih.gov), 1000 Genomes Project (http://
www.1000genomes.org), the Exome Variant Server
(http://evs.gs.washington.edu/EVS), the Exome Aggrega-
tion Consortium (http://exac.broadinstitute.org) and the
Genome Aggregation Consortium (http://gnomad.broadin
stitute.org/). The potential effect of the variants at the
protein level was predicted using PolyPhen-2 (http://gene
tics.bwh.harvard.edu/pph2).
Sequencing revealed a missense variant, c.541C>T,
p.(Arg181Trp), in exon 5 of SLC20A2, affecting a rela-
tively well conserved nucleotide (Fig. S1), predicted to be
deleterious by in silico tools and not found in European
non-Finnish control genomes (only found in one Finnish
individual in the gnomAD database, MAF = 4.1e-06).
The SLC20A2 exon 5, encoding transmembrane helix 6 of
the SLC20A2 protein, already harbors 4 other (likely)
pathogenic variants (Fig. 2). This variant was therefore
classified as likely pathogenic, according to the American
College of Medical Genetics and Genomics and the Asso-
ciation for Molecular Pathology (ACMG-AMP) guide-
lines.4 Segregation analysis confirmed the father of the
proband also carried the same variant. As he did not pre-
sent any symptoms, brain imaging was done and demon-
strated bilateral symmetric basal ganglia calcifications
(Fig. 1C). The sibs of the proband were not available for
molecular testing.
Discussion
Intracranial calcifications are common, often age-depen-
dent findings that do not lead to any medical concern.
More rarely, pathological calcifications can be associated
with infections (e.g., CMV) or be genetically determined.
Among the latter, besides syndromic forms, PFBC is an
important differential diagnosis, because of its severity
and progressive nature. The phenotypic spectrum of
PFBC is heterogeneous, including cognitive, psychiatric
and movement disorders.5 Our proband initially pre-
sented with abnormal movements and neuropsychiatric
1 2 3 4 5 6 7 8 9 1110
Exon 2: 
c.82G>A  
c.124_126del 
c.149T>G 
c.152C>T  
c.185T>C 
c.212G>A  
c.260_261del 
Exon 5: 
c.541C>T 
c.551C>T  
c.560A>G 
c.581A>G  
c.583_584del 
Exon 3: 
c.323T>C 
c.338C>G 
c.344C>T  
c.382del  
Exon 4: 
c.509delT  
c.514A>T  
c.515delA 
Exon 7: 
c.730+1G>T 
c.739C>T 
c.750delT 
c.760C>T
Exon 8: 
c.1086delC 
c.1101_1102del 
c.1138del 
c.1158C>G 
c.1187dup 
c.1207C>T 
c.1301C>G  
c.1399C>T 
c.1426G>T  
c.1492G>A  
c.1145G>A  
c.1409delC  
c.1470_1478del  
c.1483G>A 
c.1492G>A  
c.1506C>A 
c. 1520_1521del  
c.1524-2G>A
Exon 9: 
c.1527delT  
c.1618G>A 
c.1637_1638del 
c.1652G>A  
c.1703C>T 
c.1711G>A
Exon 10: 
c.1723G>A  
c.1753G>A 
c.1755_1768del 
c.1784C>T 
c.1784C>T 
Exon 11: 
c.1802C>G  
c.1802C>T 
c.1822_1848del 
c.1828_1831del 
c.1909A>C 
Figure 2. Reported (likely) pathogenic variants in the SLC20A2 gene. The exon structure of the SLC20A2 gene is shown, with the previously reported
class 4 (likely pathogenic) and class 5 (pathogenic) variants. The likely pathogenic variant found in the proband is shown in bold in exon 5.
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symptoms but developed a wide variety of additional
complaints over a two-year period.
Movement disorders are a frequent symptom of
SLC20A2-related PFBC and seem more common com-
pared to PDGFRB-associated PFBC. Parkinsonism is the
most common presenting movement disorder.6 To our
knowledge, a presentation with myoclonus has been
reported only once in brain calcification.7 Although rare,
myoclonic attacks have been associated with (atypical)
Aicardi–Goutieres syndrome which also presents with
basal ganglia calcifications 8 but have been considered to
be mainly cortical in origin because of the positive
response to piracetam.9 Our patient, however, did not
show any cortical calcifications. More recently, myoclonic
attacks and basal ganglia calcifications were described as
an unusual presentation in a young patient with a pro-
gressive neurometabolic disorder due to mutations in the
FOLR1 gene.10 Pathophysiologically, a role for the globus
pallidus could be suggested. The internal globus pallidus
inhibits the thalamocortical neurons via GABA and sub-
stance P. An increased thalamocortical drive has been
previously suggested to be involved in the development of
myoclonus.7
Pain has been associated with PFBC and, according to
Manyam et al., occurred in as much as 16% of patients,
though the precise nature of the pain sensation is not speci-
fied.11 Although it remains difficult to correlate this symp-
tom with the anatomical location of the calcified lesions, in
the absence of any neuropathic changes on the EMG, it
cannot be excluded that the neuropathic pain sensations of
the proband are part of the PFBC phenotype.
Other symptoms of the proband, which started after the
PFBC diagnosis, such as tinnitus, osteoporosis, and sen-
sorineural hearing loss are not known to be associated with
PFBC. The basal ganglia have been reported to play a role
in the pathophysiology of tinnitus, which can also be noted
in patients with secondary basal ganglia calcifications. As
the onset of the tinnitus co-occurred with the abnormal
movements, a relation with PFBC cannot be excluded.
Similarly, an inverse relation between soft tissue and
bone mineralization is well known,12 though data on the
presence or absence of a bone phenotype in PFBC are
scarce. The proband had a compression fracture of a cer-
vical vertebra due to osteoporosis. There were no known
risk factors that would make the patient more susceptible.
Blood results showed normal levels of calcitonin, magne-
sium, parathyroid hormone, phosphorus, and calcium
(Table 1). Vitamin D levels were also within normal lim-
its (53.8 pg/mL (19–95)). The risk of a fracture might
have been increased by the dysregulation of the calcium
and phosphate balance, known in PFBC. Vitamin D defi-
ciency causes osteomalacia and poor bone mineraliza-
tion.13 Hypovitaminosis D has been described in patients
with primary brain calcifications and vitamin D treatment
has been suggested to regulate SLC20A2 gene expression
and reduce brain calcification.14 Phenotypic data of the
Slc20a2 knockout mouse appears to correlate well with
the loss of functions found in PFBC patients. This
homozygous knockout model shows a variety of symp-
toms including general growth impairment, kyphosis, cat-
aract and decreased bone mineral density,15 of which the
latter two were also present in our proband.
Despite a fairly late onset of disease symptoms, the nat-
ural history of the proband was characterized by a rapid
progression of disease and complicated by mood swings
and depressive episodes, chronic headaches and vertigo –
all previously associated with PFBC – as well as an
increasing number of vague and specific complaints which
are most probably of psychosomatic nature as they could
be effectively treated with anti-depressive drugs. The
unspecified psychiatric problems reported in his sister
may be due to PFBC but no brain imaging or molecular
analysis could be obtained from this patient.
This family illustrates the important intrafamilial vari-
ability of the PFBC phenotype, though the penetrance of
the basal ganglia calcifications seems higher. PFBC has an
age-dependent radiological penetrance, reaching 95% by
age 50.2 The precise clinical penetrance has not been fully
established for the different PFBC-related genes and
pathologic variants, but may be around 70% or even
lower. According to Westenberger et al. only two-thirds
of mutation carriers develop neurologic and/or psychiatric
symptoms, while the other third could remain asymp-
tomatic throughout their lifespan.1,16 In this case, the
father of the proband, carrying the same likely pathogenic
variant and having bilateral symmetric basal ganglia calci-
fications on brain imaging, remained asymptomatic. No
correlation has been identified between age of onset,
extent of calcium deposits, and neurologic deficits. Brain
plasticity and resilience to calcification could explain why,
in some cases, the calcification anticipates symptoms by
various decades.17
In conclusion, we present a family with PFBC, harbor-
ing a likely pathogenic SLC20A2 variant and generalized
myoclonus. Movement disorders and neuropsychiatric
Table 1. Biochemical measurements in the proband.
Proband values Reference values
Calcium 2.37 2.12–2.62 mmol/L
Phosphorus 1.13 0.80–1.45 mmol/L
Magnesium 0.80 0.70–1.05 mmol/L
Parathyroid hormone 22.9 15–65 ng/L
1,25-dihydroxy vitamin D 53.8 19–95 pg/mL
L, liter; mmol, millimol; mL, milliliter; ng, nanogram; pg, picogram.
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symptoms are the hallmark symptoms that – together
with the typical basal ganglia imaging – should evoke the
diagnosis of PFBC, with generalized nonepileptic myoclo-
nus to be added to the list of presenting symptoms. The
clinical significance of several other symptoms present in
this family – some of which are recapitulated in the
Slc20a2-/- murine model – in relation to PFBC remains
to be elucidated in a larger cohort of patients.
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Figure S1. Conservation of the affected nucleotide in the
SLC20A2 gene.
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